Biotech Acquisition Co - Warrants (30/11/2027) EBIT

The latest EBIT for BIOTW is $-3.7M as of September 2022. That compares with $-1.1M in the prior-year period — down 243.2% year over year. That is above the sector sector average of $-63M. Investors often review this figure alongside Biotech Acquisition Co - Warrants (30/11/2027)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, BIOTW's EBIT moved from $-1.1M to $-3.7M — a 243.2% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Biotech Acquisition Co - Warrants (30/11/2027)'s operating scale or balance-sheet position.

Against its sector companies, BIOTW currently prints $-3.7M for EBIT, while the sector average sits near $-63M. That is roughly 94.0% above the sector mean. Large gaps often invite a closer look at Biotech Acquisition Co - Warrants (30/11/2027)'s growth, margins, and balance sheet.

A EBIT figure of $-3.7M for BIOTW is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $-63M. Explore the charts below for those layers of context.

After noting BIOTW's EBIT ($-3.7M), review year-over-year change from $-1.1M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.